Mechanisms of allergy/immunologyHypomorphic caspase activation and recruitment domain 11 (CARD11) mutations associated with diverse immunologic phenotypes with or without atopic disease
Section snippets
Patients
Informed consent was obtained from all participating patients and their family members according to protocols approved by institutional review and ethics boards at their respective institutions.
WES and genetic analysis
WES was performed in the majority of patients described here, according to established protocols. For example, kindreds 6, 19, and 29 were analyzed as follows. Genomic DNA was extracted from peripheral blood cells, and the Illumina paired-end genomic DNA sample preparation kit (PE-102-1001; Illumina, San
Novel DN CARD11 mutations detected in a broad spectrum of immune disorders
Rare or novel CARD11 mutations were identified by allergy and primary immunodeficiency referral centers in patients with immune-deficient or dysregulatory phenotypes (Table I). A total of 48 new patients in 27 families with 26 different heterozygous germline CARD11 variants were referred. Salient patient phenotypes, combined with those already reported,7, 9 are summarized in Tables I and II. These alleles were then evaluated at centers specializing in CARD11 biology and associated diseases and
Discussion
In this report we describe multiple new DN CARD11 mutations associated with additional immunodeficient and dysregulatory conditions in human patients. Recent reports identified DN CARD11 mutations in a handful of patients presenting with severe AD and other allergic conditions with or without additional infections.7, 9 The substantially larger cohort assembled here illuminates a broader phenotypic spectrum of disease tied to CARD11 DN mutations, including frequent sinopulmonary infections,
References (41)
- et al.
The CARD11-BCL10-MALT1 (CBM) signalosome complex: stepping into the limelight of human primary immunodeficiency
J Allergy Clin Immunol
(2014) - et al.
Combined immunodeficiency and atopy caused by a dominant negative mutation in caspase activation and recruitment domain family member 11 (CARD11)
J Allergy Clin Immunol
(2018) - et al.
Identifying the MAGUK protein Carma-1 as a central regulator of humoral immune responses and atopy by genome-wide mouse mutagenesis
Immunity
(2003) - et al.
CARMA1 coiled-coil domain is involved in the oligomerization and subcellular localization of CARMA1 and is required for T cell receptor-induced NF-kappaB activation
J Biol Chem
(2007) - et al.
Exome and genome sequencing for inborn errors of immunity
J Allergy Clin Immunol
(2016) - et al.
Plasma cell deficiency in human subjects with heterozygous mutations in Sec61 translocon alpha 1 subunit (SEC61A1)
J Allergy Clin Immunol
(2018) - et al.
Online system for faster multipoint linkage analysis via parallel execution on thousands of personal computers
Am J Hum Genet
(2006) - et al.
Omenn syndrome associated with a functional reversion due to a somatic second-site mutation in CARD11 deficiency
Blood
(2015) - et al.
TCR signaling to NF-kappaB and mTORC1: expanding roles of the CARMA1 complex
Mol Immunol
(2015) - et al.
Whole-exome sequencing links caspase recruitment domain 11 (CARD11) inactivation to severe combined immunodeficiency
J Allergy Clin Immunol
(2013)
Deficiency of caspase recruitment domain family, member 11 (CARD11), causes profound combined immunodeficiency in human subjects
J Allergy Clin Immunol
Cooperative control of caspase recruitment domain-containing protein 11 (CARD11) signaling by an unusual array of redundant repressive elements
J Biol Chem
Intramolecular interactions and regulation of cofactor binding by the four repressive elements in the caspase recruitment domain-containing protein 11 (CARD11) inhibitory domain
J Biol Chem
Human RAG mutations: biochemistry and clinical implications
Nat Rev Immunol
Role of the CARMA1/BCL10/MALT1 complex in lymphoid malignancies
Curr Opin Hematol
Lymphocyte signaling and activation by the CARMA1-BCL10-MALT1 signalosome
Biol Chem
Impaired control of Epstein–Barr virus infection in B-Cell expansion with NF-κB and T-cell anergy disease
Front Immunol
Congenital B cell lymphocytosis explained by novel germline CARD11 mutations
J Exp Med
Germline hypomorphic CARD11 mutations in severe atopic disease
Nat Genet
Clustering of CARMA1 through SH3-GUK domain interactions is required for its activation of NF-kappaB signalling
Nat Commun
Cited by (108)
Monogenic etiologies of persistent human papillomavirus infections: A comprehensive systematic review
2024, Genetics in MedicineNF-κB and Related Autoimmune and Autoinflammatory Diseases
2023, Rheumatic Disease Clinics of North AmericaA novel variant in caspase recruitment domain family member 11 highlights the variability of clinical manifestations and management in a three generation family
2023, Journal of Allergy and Clinical Immunology: In PracticeThe Rapidly Expanding Genetic Spectrum of Common Variable Immunodeficiency–Like Disorders
2023, Journal of Allergy and Clinical Immunology: In PracticeSkin barrier immunology from early life to adulthood
2023, Mucosal Immunology
Supported in part by the Intramural Research Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID), National Library of Medicine; German BMBF grants 01E01303 and 01ZX1306F; the DZIF (TTU 07.801); NIAID extramural award R21AI109187; the SFB1160 (IMPATH); and National Health and Medical Research Council (Australia) grants 1113577 and 1079648.
Disclosure of potential conflict of interest: S. Ehl receives research support from BMBF, the Canadian Immunodeficiency Society, and the European Union's Horizon 2020 Research and Innovation Programme; serves as a consultant for UCD and Novartis but not in the context of this study; and received payments from lectures for CSL Behring. P. D. Arkwright receives travel support from Allergy Therapeutics and Nutricia. T. R. Leahy serves as a consultant for Baxalta. N. Conlon received payment for lectures from Baxalta, Novartis, and GlaxoSmithKline and received travel funds from Baxalta. T. R. Torgerson has consultant arrangements with Baxalta Biosciences, CSL Behring, and ADMA Biosciences; has received grants from Baxalta Biosciences, CSL Behring, and the National Institutes of Health (NIH); and has received payment for lectures from Baxalta Biosciences, CSL Behring, Questcor Pharmaceuticals, and the Robert Wood Johnson Foundation. B. Grimbacher receives grant support from BMBF, the European Union, Helmholtz, DFG, DLR, and DZIF; is an employee of UKL-FR; and receives payments for lectures from CSL-Behring, Baxalta, Shire, Biotest, Octopharma, Kedrion, and Grifols. M. C. Cook has received research support from the National Health and Medical Research Council, Australia. A. L. Snow receives grant support from the NIH. The rest of the authors declare that they have no relevant conflicts of interest.
- ∗
These authors contributed equally to this work.